



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kinzler and Vogelstein

Serial No. 09/966,724

Filed: October 1, 2001

)  
)  
)  
)  
)  
)

Examiner: Jon Ashen

Group Art Unit: 1635

Atty. Dkt. No. 01107.00193

For: AMPLIFICATION OF HUMAN MDM2 GENE IN HUMAN TUMORS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98**

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

The attached two PTO Forms-1449 list documents for the Examiner's consideration.

Copies of the documents are included. If a fee is required, charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: 24 February 2006

By: Lisa M. Hemmendinger  
Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of

2

### Complete If Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		6,238,921		Miraglia <i>et al.</i>	May 29, 2001	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bartel <i>et al.</i> , "MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides," <i>Mol. Cancer Res.</i> 2, 29-35, January 2004	
		Capoulade <i>et al.</i> , "Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides," <i>Blood</i> 97, 1043-49, February 15, 2001	
		Chen <i>et al.</i> , "Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage," <i>Proc. Natl. Acad. Sci. USA</i> 95, 195-200, January 1998	
		Fiddler <i>et al.</i> , "Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis," <i>Mol. Cell. Biol.</i> 16, 5048-57, September 1996	
		Goetz <i>et al.</i> , "Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells," <i>Cancer Res.</i> 61, 7635-41, October 15, 2001	
		Sato <i>et al.</i> , "Enhancement of Drug Induced Apoptosis by Antisense Oligodeoxynucleotides Targeted against Mdm2 and p21 <sup>WAF1/CIP1</sup> ," <i>Anticancer Research</i> 20, 837-42, 2000	
		Uhlmann & Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem Rev.</i> 90, 543-84, 1990	
		Wang <i>et al.</i> , "MDM2 oncogene as a target for cancer therapy: An antisense approach," <i>Int. J. Oncol.</i> 15, 653-60, 1999	

Examiner  
Signature

Date  
Considered

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of

2

### Complete if Known

Application Number	09/966,724
Filing Date	October 1, 2001
First Named Inventor	Kinzler
Group Art Unit	1635
Examiner Name	Jon Ashen
Attorney Docket Number	001107.00193

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		6,238,921		Miraglia <i>et al.</i>	May 29, 2001	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Wang <i>et al.</i> , "Antisense Anticancer Oligonucleotide Therapeutics," <i>Current Cancer Drug Targets</i> 1, 177-96, 2001	
		Wang <i>et al.</i> , "Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides," <i>Ann. N.Y. Acad. Sci.</i> 1002, 217-35, 2003	
		Zang & Wang, "Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression," in <i>Methods in Molecular Medicine 85: Novel Anticancer Drug Protocols</i> , pages 205-22, Buolamwini & Adjei, eds., Humana Press, 2003	

Examiner  
Signature

Date  
Considered